The antibody drug conjugates contract manufacturing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Antibody Drug Conjugates Contract Manufacturing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The antibody drug conjugates contract manufacturing market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.57 billion in 2024 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing prevalence of cancer, growing demand for targeted therapies, improvements in antibody drug conjugates, rising investment in research and development, regulatory approvals of new ADCs, and the expansion of pharmaceutical companies.
The antibody drug conjugates contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $14.00 billion in 2028 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to anticipated growth of personalized medicine, expanding applications beyond oncology, increasing collaborations between biotech and pharma companies, rising adoption of ADCs in clinical trials, growing emphasis on cost-effective manufacturing solutions. Major trends in the forecast period include advancements in biomarker identification, advancements in biotechnology, rising adoption of next-generation ADC technologies, advancements in linker and payload technologies, integration of artificial intelligence for drug development.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-contract-manufacturing-global-market-report
Scope Of Antibody Drug Conjugates Contract Manufacturing Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Antibody Drug Conjugates Contract Manufacturing Market Overview
Market Drivers –
The growing biopharmaceutical industry is expected to propel the growth of the antibody-drug conjugates contract manufacturing market going forward. The biopharmaceutical industry is a sector focused on developing, producing, and commercializing drugs derived from biological sources, utilizing biotechnology and molecular biology to create innovative therapies and treatments. The biopharmaceutical industry is increasing due to rapid advancements in biotechnology, growing demand for personalized medicine, and rising investments in research and development for innovative therapies and treatments. Antibody-drug conjugates (ADCs) contract manufacturing supports the biopharmaceutical industry by offering specialized production services that facilitate developing and commercializing these advanced therapies. Biopharmaceutical companies can efficiently scale up production and ensure high-quality standards while concentrating on their core areas of research and development. For instance, in May 2024, according to the Department of Health and Social Care, a UK-based government department, the core biopharmaceutical sector earned £46.7 billion ($59.32 billion) in revenue in 2021/22, accounting for 43% of the whole life sciences industry. Therefore, the growing biopharmaceutical industry drives the growth of the antibody-drug conjugates contract manufacturing market.
Market Trends –
Major companies operating in the antibody-drug conjugates contract manufacturing market are focused on developing innovative products, such as single-use reactors, to enhance production flexibility, reduce contamination risks, and streamline the manufacturing process, ultimately improving the efficiency and scalability of ADC production. Single-use reactors are revolutionizing the field of antibody-drug conjugates (ADCs) contract manufacturing by providing a flexible, efficient, and contamination-free solution for producing these complex biologics. For instance, in September 2024, MilliporeSigma, a US-based life science company, launched the Mobius ADC Reactor, a single-use reactor. Mobius ADC Reactor is specifically designed to manufacture antibody-drug conjugates (ADCs) efficiently. The Mobius ADC Reactor integrates advanced mixing and control technologies that streamline conjugation, enhance scalability, and improve consistency. This innovative reactor supports higher yields and better quality control in ADC production, addressing the growing demand for targeted cancer therapies with improved safety and efficacy.
The antibody drug conjugates contract manufacturing market covered in this report is segmented –
1) By Type: Immunoglobulin G1(Igg1), Immunoglobulin G4(Igg4)
2) By Linker: Cleavable Linker, Non-Cleavable Linker
3) By Condition: Myeloma, Lymphoma, Breast Cancer, Other Conditions
4) By Phase: Clinical, Commercial
Get an inside scoop of the antibody drug conjugates contract manufacturing market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18954&type=smp
Regional Insights –
North America was the largest region in the antibody drug conjugates contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody drug conjugates contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the antibody drug conjugates contract manufacturing market are AbbVie Inc., Eli Lilly and Company, Gilead Sciences Inc., Merck KGaA, Boehringer Ingelheim, Recipharm AB, Sigma-Aldrich, Sartorius AG, Curia, Lonza Group AG, Catalent Inc., KBI Biopharma, Alcami Corporation, Formosa Laboratories, BioVectra Inc., Axplora, Abzena PLC, ImmunoGen Inc., EirGenix Inc., Avid Bioservices Inc., Mersana Therapeutics, Cerbios-Pharma SA, Creative Biolabs, Aurigene Pharmaceutical Services Ltd., Sterling Pharma Solutions
Table of Contents
1. Executive Summary
2. Antibody Drug Conjugates Contract Manufacturing Market Report Structure
3. Antibody Drug Conjugates Contract Manufacturing Market Trends And Strategies
4. Antibody Drug Conjugates Contract Manufacturing Market – Macro Economic Scenario
5. Antibody Drug Conjugates Contract Manufacturing Market Size And Growth
…..
27. Antibody Drug Conjugates Contract Manufacturing Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
